The method’s compatibility with DBS samples, coupled with its minimized Hct effect, offers a practical and reliable approach for clinical implementation, potentially improving patient adherence and treatment outcomes in hormone receptor-positive, HER2-negative breast cancer therapy. The gene discussed is ERBB2; the disease is breast carcinoma.